HPS Pharmacies wish to advise that all suppliers are experiencing a supply interruption for prazosin 1mg and 2mg tablets, as follows:
| Product | ARTG | Estimated return date |
| APO-Prazosin 1 mg | 73858 | End-August 2025 |
| APO-Prazosin 2 mg | 73862 | End-August 2025 |
| Minipress 1 mg | 10756 | End-January 2026 |
| Minipress 2 mg | 10757 | End-January 2026 |
Minipress® 5mg tablets are currently available.
The Therapeutic Goods Administration (TGA) has authorised the supply of a Section 19A alternative for the 1mg and 2mg tablets. These products are registered in the USA and all labelling is in English. Both of the S19A alternatives are presented in capsule form (the Australian registered products are tablets).
Please note that S19A products may have a longer lead time as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates